Concentrx Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Durham NC United States (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2017
NCT03373409
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

BioEclipse Therapeutics | Concentrx Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

albuterol (proventil) (2 trials)

Drugs in Phase 1 Trials (1)

crx100 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Osteosarcoma (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2